Control of radiation injury
Abstract
The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.
Claims
exact text as granted — not AI-modified1 .- 14 . (canceled)
15 . An autoinjector for administering a parenteral composition, the improvement comprising, including in said autoinjector, adapted for injection, means for treating or preventing radiation injury.
16 . The autoinjector of claim 15 , wherein the means for treating or preventing radiation injury comprises a peptide, or functional analogue or derivative thereof, of smaller than thirty (30) amino acids.
17 . The autoinjector of claim 16 wherein the means for treating or preventing radiation injury comprises a peptide, the peptide being smaller than fifteen (15) amino acids.
18 . The autoinjector of claim 17 wherein the peptide is smaller than seven (7) amino acids.
19 . The autoinjector of claim 18 wherein the peptide consists of from two (2) to six (6) amino acids.
20 . The autoinjector of claim 19 , wherein the peptide consists of from three (3) to five (5) amino acids.
21 . The autoinjector of claim 20 wherein the peptide consists of four (4) amino acids.
22 . The autoinjector of claim 16 , wherein the radiation injury comprises acute radiation injury.
23 . The autoinjector of claim 16 , wherein said radiation injury comprises damage of the lining of the intestinal tract of said subject, the so-called gastrointestinal syndrome.
24 . The autoinjector of claim 16 , wherein the peptide has a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by
a. testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with the peptide at 72 hours after WBI and, b. testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of the peptide at 72 hours after WBI and, c. wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.
25 . The autoinjector of claim 24 wherein the peptide has a DRF of at least 1.20 or at least 1.25.
26 . The autoinjector of claim 16 , wherein said radiation injury is irradiation injury.
27 . The autoinjector of claim 16 , wherein said radiation is emitted by radioactive substances.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.